Get the app
USHealthcare

Geron Corporation (GERN)

US · Healthcare · Biotechnology

$1.32+2.33%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$57.5M
Revenue YoY
+17.2%
Net profit
$-16.7M
EPS
$-0.02
EPS estimate
$-0.01
Net margin
-29.0%

EPS came in at -0.02 against a street estimate of -0.01 — a miss of 100.0%.

Key statistics

Market cap
$828.8M
Forward P/E
65.4
P/B
3.85
Book value
$0.34
EPS (TTM)
$-0.11
52-week high
$2.01
52-week low
$1.04
50-day MA
$1.47
200-day MA
$1.45
Beta
0.60

Analyst view

Analysts rate Geron Corporation a buy (6 buy, 3 hold, 0 sell out of 9) with an average price target of $4.25.

Shareholding

Insiders
0.08%
Institutions
76.69%

Largest institutional holders

FundStake
RA Capital Management, LLC9.93%
BlackRock Inc7.37%
Soleus Capital Management, L.P.6.66%
State Street Corp4.75%
Vanguard Capital Management, LLC4.15%
Citadel Advisors Llc3.36%
Point72 Asset Management, L.P.3.18%
ClearBridge Advisors, LLC3.05%

Recent filings & reports

DocumentDate
Results announced · Q3 2026
GERON CORPORATION Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 RYTELO net product revenue: $57.5 million (11% increase vs Q1 2026) •
2026-08-06
Quarterly report · Q2 2026
GERON CORPORATION – FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and marketable securities combined: $326.9 million (J
2026-08-05
Board / officer change · Q2 2026
GERON CORPORATION – 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held May 20, 2026 (virtual format) • 4,500,000 new shares authorized u
2026-05-27
Quarterly report · Q1 2026
GERON CORPORATION – Q1 2026 SUMMARY HEADLINE NUMBERS • Product Revenue (Q1 2026): $51.8 million total revenues (product: $51.8M, royalties: $66K), u
2026-05-06
Proxy statement · Q2 2026
GERON CORPORATION PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three directors to Class III Board positions (serving
2026-04-07
Board / officer change · Q1 2026
GERON CORPORATION - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Geron Corporation (ticker: GERN, Nasdaq) elected two new Class III directors to its
2026-03-26
Annual report FY2025
GERON CORPORATION FORM 10-K SUMMARY HEADLINE NUMBERS • Market value of non-affiliate shares: approximately $860,500,000 (as of June 30, 2025) • Outs
2026-03-02
Results announced · Q1 2026
GERON CORPORATION – 2025 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • RYTELO net product revenue: $48.0 million in Q4 2025; $183.6 million for full
2026-02-25

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Geron Corporation — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.